You are here: Home » Companies » News
Business Standard

Lupin gets USFDA nod for marketing testosterone topical solution

Testosterone topical solution are indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone

Press Trust of India  |  New Delhi 

Lupin
Lupin

Drug firm on Wednesday said it has received the final approval from the for its

The company has received final approval for its testosterone topical solution, 30 mg per actuation from the United States Food and Drug Administration (USFDA) to market the product, said in a filing.

The approved product is a generic version of Eli Lilly and Company's Axiron topical solution, it added.

According to IMS MAT June 2017 data, had sales of $244.2 million in the US, said.

The are indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone, it added.

Shares of were trading at Rs 1028.50, up 0.19 per cent from the previous close on


First Published: Wed, October 25 2017. 11:59 IST
RECOMMENDED FOR YOU